[Oral Smeglutide was approved for marketing in China] On January 26, Novo Nordisk Smeglutide tablets were approved for marketing by the National Drug Administration (NMPA) for the treatment of type 2 diabetes. This is the first domestically approved oral GLP-1 (glucagon like peptide-1) receptor agonist.